Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pro-apoptotic carboxamide analogues of natural fislatifolic acid targeting Mcl-1 and Bcl-2.
Gapil Tiamas S, Daressy F, Abou Samra A, Bignon J, Steinmetz V, Litaudon M, Fourneau C, Hoong Leong K, Ariffin A, Awang K, Desrat S, Roussi F. Gapil Tiamas S, et al. Among authors: daressy f. Bioorg Med Chem Lett. 2020 Apr 1;30(7):127003. doi: 10.1016/j.bmcl.2020.127003. Epub 2020 Feb 3. Bioorg Med Chem Lett. 2020. PMID: 32035700
NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
Daressy F, Séguy L, Favre L, Corvaisier S, Apel C, Groo AC, Litaudon M, Dumontet V, Malzert-Fréon A, Desrat S, Roussi F, Robert A, Wiels J. Daressy F, et al. Biomed Pharmacother. 2022 Oct;154:113546. doi: 10.1016/j.biopha.2022.113546. Epub 2022 Aug 18. Biomed Pharmacother. 2022. PMID: 35988426 Free article.
In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.
Séguy L, Daressy F, Lahlil S, Corvaisier S, Dumontet V, Litaudon M, Apel C, Roussi F, Wiels J, Robert A, Groo AC, Malzert-Fréon A. Séguy L, et al. Among authors: daressy f. Int J Pharm. 2023 Jan 5;630:122433. doi: 10.1016/j.ijpharm.2022.122433. Epub 2022 Nov 24. Int J Pharm. 2023. PMID: 36436745